Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial – The Lancet Respiratory Medicine Commentaries: Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial – The Lancet Respiratory Medicine Rheumatoid Arthritis Drug Combined with Standard of Care May […]

The post RCT: Baricitinib reduced mortality in hospitalized adults with COVID-19. appeared first on Links Medicus.